UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
ACXP holding history
Acurx Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ACXP overviewAll 13F holders of ACXPFull Q2 2026 holdings
- Shares (Q2 2026)
- 3
- Value
- $5
- % of portfolio
- <0.1%
- Quarters held
- 11
- Since Q2 2022
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 3 | $5 | <0.1% | −6,309−100.0% | Reduced | Holders |
| Q1 2026 | 6,312 | $23.4K | <0.1% | +6,143+3,634.9% | Added | Holders |
| Q4 2025 | 169 | $420 | <0.1% | +169 | New | Holders |
| Q3 2025 | 0 | $0 | 0.0% | −1,938−100.0% | Sold outConverted for a 1-for-20 split | Holders |
| Q2 2025 | 38,759 | $19.8K | <0.1% | +38,712+82,366.0% | Added | Holders |
| Q1 2025 | 47 | $18 | <0.1% | −5,914−99.2% | Reduced | Holders |
| Q4 2024 | 5,961 | $4.85K | <0.1% | +5,961 | New | Holders |
| Q3 2024 | 0 | $0 | 0.0% | −881−100.0% | Sold out | Holders |
| Q2 2024 | 881 | $1.98K | <0.1% | +881 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −2,904−100.0% | Sold out | Holders |
| Q1 2023 | 2,904 | $10.0K | <0.1% | +168+6.1% | Added | Holders |
| Q4 2022 | 2,736 | $10.9K | <0.1% | −1,353−33.1% | Reduced | Holders |
| Q3 2022 | 4,089 | $12.0K | <0.1% | +3,048+292.8% | Added | Holders |
| Q2 2022 | 1,041 | $4.00K | <0.1% | +1,041 | New | Holders |